

NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES

DESPATCH OF RETAIL OFFER DOCUMENT

PERTH, Australia – 24 February 2025

PYC Therapeutics Limited (ASX:PYC) advises that it has today despatched the Retail Offer Booklet relating to the accelerated non-renounceable entitlement offer announced to the Australian Securities Exchange (ASX) on 17 February 2025. A copy of the Retail Offer Booklet was released to the ASX today.

Commencement of the Retail Entitlement Offer

The retail component of the Entitlement Offer (**Retail Entitlement Offer**) will open today, Monday 24 February 2025 and will close at 5.00pm (AWST) on Friday, 14 March 2025 (unless varied).

Eligible shareholders on the record date of 4.00pm (AWST) on Wednesday, 19 February 2025, may participate in the Retail Entitlement Offer at the Issue Price of \$1.25 per New Share, on the basis of 1 New Share for every 4 Existing Shares held.

Retail Investor Enquiries

If you have any queries concerning the Retail Entitlement Offer, or the action you are required to take to subscribe for New Shares, please consult your stockbroker, accountant, solicitor or other professional advisor. For Further information about the Retail Entitlement Offer you can call Automic Share Registry on 1300 228 664 (within Australia) or +61 2 9698 5414 (outside Australia) from 5.30am to 5.00pm (Perth time) Monday to Friday during the Retail Offer Period.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class.

PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**¹.

For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

CONTACTS:

INVESTORS and MEDIA

Investor@pyctx.com

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.20222232>